Mizuho lowered the firm’s price target on Nkarta (NKTX) to $16 from $20 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm removed the potential contribution of NKX019 in large B-cell malignancies, upon Nkarta announcing that it will no longer further development in this indication.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.